Multiple Myeloma Research Consortium Initiates Phase 1B Study Of Elotuzumab Monoclonal Antibody...

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID® (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the maximum tolerated dose of elotuzumab in combination with label dosing of lenalidomide and dexamethasone. The multi-center, open-label, dose-escalation Phase Ib study will enroll up to 26 patients. "This three drug combination study is a pivotal study for patients with relapsed... [read full story]